chf.jpg
CHF Solutions and RenalSense Enter Distribution Partnership to Offer Ultrafiltration and Real-Time Renal Diagnostics
July 08, 2020 09:25 ET | CHF Solutions, Inc.
EDEN PRAIRIE, Minn., July 08, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) and RenalSense, Ltd., today announced the signing of a distribution agreement to offer complementary solutions for...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Third Quarter 2019 Financial Results
October 31, 2019 17:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel,...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics and ArTara Therapeutics Agree to Combine
September 23, 2019 16:20 ET | Proteon Therapeutics, Inc.
Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Second Quarter 2019 Financial Results
August 07, 2019 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to...
gmi 2018.png
Worldwide Stent Market value worth $16 billion by 2025: Global Market Insights, Inc.
June 10, 2019 04:42 ET | Global Market Insights, Inc
Selbyville, Delaware, June 10, 2019 (GLOBE NEWSWIRE) -- Bioresorbable stent market will grow at 7.8% over the projected period. Bioresorbable stents get absorbed in the body after serving its...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces First Quarter 2019 Financial Results
May 08, 2019 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Review of Potential Strategic Transactions
April 15, 2019 16:30 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
March 28, 2019 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
March 13, 2019 08:00 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., March 13, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
New Proteon Logo - full color RGB.jpg
Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th
March 04, 2019 16:30 ET | Proteon Therapeutics, Inc.
WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...